Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02048059 · ClinicalTrials.gov registry record · Phase 2
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase 2 study of Breast Cancer and Brain Metastases, sponsored by Angiochem.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 19
- Study locations
NCT02048059 is a Phase 2 study of Breast Cancer and Brain Metastases that has completed, run by Angiochem. The registered enrollment target is 72 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 19 study locations across 13 states.
The verdict
NCT02048059, a Phase 2 study of Breast Cancer and Brain Metastases, has completed, sponsored by Angiochem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
Conditions Studied
Interventions
- DRUG ANG1005
Study Locations (19)
California
- UC San Diego Moores Cancer Center - La Jolla
- University of California - LAC Medical Center - Los Angeles
- University of Southern California - Norris Comprehensive Cancer Center - Los Angeles
- UC - Irvine Chao Family Comprehensive Cancer Center - Orange
Maryland
- University of Maryland - Greenebaum Cancer Center - Baltimore
- National Cancer Institute - Bethesda
Pennsylvania
- Magee Womens Hospital - Pittsburgh
- UPMC Cancer Center - Pittsburgh
Texas
- MD Anderson Cancer Center - Houston
- Univeristy of Texas Health Science Center in San Antonio - San Antonio
Arizona
- University of Arizona Cancer Center - Tucson
Colorado
- University of Colorado Cancer Center - Aurora
Georgia
- GRU Cancer Center - Georgia Regents University - Augusta
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02048059
The ClinicalTrials.gov registry entry for NCT02048059 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Angiochem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ANG1005 is the first listed.
NCT02048059 reports 19 study locations spanning 13 distinct geographic areas - top geographies include California, Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02048059 about?
NCT02048059 is a clinical study titled "ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases". This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
What is the current status of trial NCT02048059?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2014-04. Estimated completion is 2017-09.
What conditions does trial NCT02048059 study?
This clinical trial studies the following conditions: Breast Cancer, Brain Metastases.
What interventions are being tested in trial NCT02048059?
The interventions under investigation include: ANG1005 (DRUG).
Who is sponsoring clinical trial NCT02048059?
This trial is sponsored by Angiochem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02048059 being conducted?
This trial has 19 study locations across Arizona, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.